EUTOS Score for Chronic Myelogenous Leukemia (CML)
Predict outcomes after CML treatment, adjusted for tyrosine kinase treatments
The EUTOS Score was derived from a cohort of 2060 patients enrolled in studies of first-line treatment with imatinib-based regimens. The EUTOS score using the percentage of basophils and spleen size best discriminated between high-risk and low-risk groups of patients, with a positive predictive value of not reaching a CCgR of 34%.
- [1]Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.: Predicting Complete Cytogenetic Response and Subsequent Progression-Free Survival in 2060 Patients With CML on Imatinib Treatment: The EUTOS Score.2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038. Epub 2011 May 2.
Results
Real-time automated computation
The EUTOS Score was derived from a cohort of 2060 patients enrolled in studies of first-line treatment with imatinib-based regimens. The EUTOS score using the percentage of basophils and spleen size best discriminated between high-risk and low-risk groups of patients, with a positive predictive value of not reaching a CCgR of 34%.
- [1]Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.: Predicting Complete Cytogenetic Response and Subsequent Progression-Free Survival in 2060 Patients With CML on Imatinib Treatment: The EUTOS Score.2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038. Epub 2011 May 2.